Search

Sarcomas of the extremities are rare entities, the treatment of which requires special expertise. Even if the treatment of patients is always interdisciplinary, the surgical R0 resection is the key point of each curatively intended treatment. In addition to resection in sano, the aim is to preserve the extremities and function, so that defect reconstruction after resection plays a decisive role. Due to the heterogeneity of tumors as well as their localization and extent, reconstruction is always an individually adapted treatment. Modular tumor endoprostheses are often used in this context, which can be constructed according to the size of the defect. The transplantation of autologous or allogeneic bone is also frequently used alone or as an additive procedure. Patient-specific (mega)prostheses are used particularly for pelvic tumors. Defect reconstruction using scaffold-based procedures from the field of tissue engineering is being tested as a promising procedure for the future. This article provides an overview of the treatment principles for sarcomas of the extremities and their individual reconstruction options. [ABSTRACT FROM AUTHOR]

The German Ethics Council has published recommendations for the ethically responsible use of Artificial Intelligence (AI) in medicine. The statement emphasizes the need for a comprehensive examination of the ethical aspects of AI and new technologies. Various applications of AI in medicine are presented, such as pattern recognition in cancer diagnosis and therapy chatbots. The authors emphasize the importance of evaluating the impact of AI on responsibility and human authorship. Various actors are mentioned who should be involved in the development and application process of AI systems, and the importance of data protection standards and clear regulations for data usage is highlighted. It is emphasized that the competence of doctors and personal care remain of great importance and that ethical standards must be adhered to in order to ensure the well-being of patients. [Extracted from the article]

The article offers an analysis of the benefits of HER2 targeted therapies for the prognosis of patients with HER2-positive breast cancer. It mentions those affected with low HER2 expression could also benefit from therapy with antibody-drug conjugates (ADCs). It also mentions HER2 overexpression or amplification occurs in various tumor entities, and is associated with more aggressive tumor growth and lower overall survival rates without appropriate targeted therapy.

The article titled "Liability of the gynecologist and radiologist for delayed treatment initiation in case of breast cancer" deals with the case of a patient who died from liver failure due to liver metastases of breast cancer as a result of delayed treatment initiation. The gynecologist and radiologist were held liable for treatment and information errors. The gynecologist had read the radiologist's findings but did not inform the patient about the urgent need for further clarification. The radiologist had suggested that no further clarification was necessary, although the mammography examination showed abnormal results. The lower courts awarded compensation to the patient's children and established the liability of both doctors. [Extracted from the article]

The article "Melanomas: Preserving Resting Phase and Preventing Relapse" reports on a new research finding in the field of cancer therapy. Researchers have discovered a protein called KDM5B that plays a role in the resting phase of melanoma cells. By using a substance called Cpd1, the researchers were able to inhibit the flexibility of the cells and allow an additional cancer medication to fully take effect. This double-strike strategy could be a significant advancement in cancer therapy, but it still needs to be confirmed in clinical studies. [Extracted from the article]